Group 1 - Johnson & Johnson (NYSE: JNJ) has seen its shares increase by 46% year-to-date and has reported significant developments in December, including FDA approval for its AKEEGA drug for prostate cancer treatment [2] - The firm announced an 83% reduction in disease risk or death for patients with relapsed/refractory multiple myeloma (RRMM) from its phase three study of TECVAYLI and DARZALEX FASPRO drugs [2] - Bank of America raised its price target for Johnson & Johnson to $220 from $204 while maintaining a Neutral rating, reflecting analyst enthusiasm for the company's cancer drug portfolio [3] Group 2 - Jim Cramer praised Johnson & Johnson for its strategic decision to spin off its orthopaedics business, indicating that the company is making the right moves by focusing on higher-margin products [3]

Core Insights - Halozyme Therapeutics, Inc. (NASDAQ:HALO) is recognized as a highly profitable biotech stock with a maintained Buy rating and a price target of $90 by H.C. Wainwright analyst Mitchell Kapoor [1][2] Company Overview - Halozyme Therapeutics, Inc. operates as a biopharmaceutical technology platform company, focusing on the development, manufacturing, and commercialization of drug-device combination products utilizing advanced auto-injector technology [4] Growth Potential - The company's growth potential is supported by the recent success of the MajesTEC-3 trial, which demonstrated significant improvements in progression-free survival (PFS) and overall survival (OS) compared to existing treatments [2][3] - The MajesTEC-3 trial combines Johnson & Johnson's DARZALEX Faspro with TECVAYLI, enhancing Halozyme's royalty base and providing strong evidence for DARZALEX-based regimens, which leverage the company's ENHANZE technology [3]